10171 related articles for article (PubMed ID: 11687850)
1. Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
Gershtein ES; Medvedeva SV; Babkina IV; Kushlinskii NE; Trapeznikov NN
Bull Exp Biol Med; 2001 Jul; 132(1):670-4. PubMed ID: 11687850
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
3. Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
Gershtein ES; Kushlinskii NE
Bull Exp Biol Med; 2001 Jan; 131(1):67-72. PubMed ID: 11329087
[TBL] [Abstract][Full Text] [Related]
4. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
5. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activation in melanocytic neoplasia.
Delbaldo C; Masouye I; Saurat JH; Vassalli JD; Sappino AP
Cancer Res; 1994 Aug; 54(16):4547-52. PubMed ID: 8044805
[TBL] [Abstract][Full Text] [Related]
7. [Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases].
Kushlinskiĭ NE; Gershteĭn ES; Kazantseva IA; Kharitidi TIu; Liakina LT; Kazakov SP; Bagatyrev OP; Kalinin AP
Vestn Ross Akad Med Nauk; 2001; (5):32-4. PubMed ID: 11510147
[TBL] [Abstract][Full Text] [Related]
8. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
[TBL] [Abstract][Full Text] [Related]
9. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours.
Arai Y; Kubota T; Nakagawa T; Kabuto M; Sato K; Kobayashi H
Acta Neurochir (Wien); 1998; 140(4):377-85; discussion 385-6. PubMed ID: 9689330
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Kushlinskii NE; Yusifov AI; Gershtein ES; Solov'ev YN; Trapeznikov NN
Bull Exp Biol Med; 2001 Aug; 132(2):780-2. PubMed ID: 11713566
[TBL] [Abstract][Full Text] [Related]
11. Urokinase and tissue plasminogen activators and their PAI-1 inhibitor in tumors of patients with oral mucosal cancer: relationship with the main clinical morphological factors.
Gershtein ES; Batsev AF; Matyakin EG; Kushlinskii NE
Bull Exp Biol Med; 2010 Sep; 149(3):347-50. PubMed ID: 21246098
[TBL] [Abstract][Full Text] [Related]
12. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Sier CF; Vloedgraven HJ; Ganesh S; Griffioen G; Quax PH; Verheijen JH; Dooijewaard G; Welvaart K; van de Velde CJ; Lamers CB
Gastroenterology; 1994 Nov; 107(5):1449-56. PubMed ID: 7926508
[TBL] [Abstract][Full Text] [Related]
13. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
14. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
[TBL] [Abstract][Full Text] [Related]
15. Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
Maguire T; Chin D; Soutar D; Duffy MJ
Int J Cancer; 2000 Feb; 85(4):457-9. PubMed ID: 10699914
[TBL] [Abstract][Full Text] [Related]
16. Oxygen modulates the release of urokinase and plasminogen activator inhibitor-1 by retinal pigment epithelial cells.
Erichsen JT; Jarvis-Evans J; Khaliq A; Boulton M
Int J Biochem Cell Biol; 2001 Mar; 33(3):237-47. PubMed ID: 11311855
[TBL] [Abstract][Full Text] [Related]
17. Regulation and interactions in the activation of cell-associated plasminogen.
Myöhänen H; Vaheri A
Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Ramont L; Pasco S; Hornebeck W; Maquart FX; Monboisse JC
Exp Cell Res; 2003 Nov; 291(1):1-10. PubMed ID: 14597403
[TBL] [Abstract][Full Text] [Related]
19. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
[TBL] [Abstract][Full Text] [Related]
20. The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.
Herszényi L; Plebani M; Cardin R; Carraro P; De Paoli M; Roveroni G; Naccarato R; Farinati F
Acta Physiol Hung; 1995; 83(3):213-21. PubMed ID: 8852646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
